Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C, Atyeo C, Loos C, Chandrashekar A, McMahan K, Tostanoski LH, Yu J, Gebre MS, Jacob-Dolan C, Li Z, Patel S, Peter L, Liu J, Borducchi EN, Nkolola JP, Souza M, Tan CS, Zash R, Julg B, Nathavitharana RR, Shapiro RL, Azim AA, Alonso CD, Jaegle K, Ansel JL, Kanjilal DG, Guiney CJ, Bradshaw C, Tyler A, Makoni T, Yanosick KE, Seaman MS, Lauffenburger DA, Alter G, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H, Barouch DH.
Stephenson KE, et al. Among authors: struyf f.
JAMA. 2021 Apr 20;325(15):1535-1544. doi: 10.1001/jama.2021.3645.
JAMA. 2021.
PMID: 33704352
Free PMC article.
Clinical Trial.